South & Central America Stem Cell Therapy Market

The South & Central America stem cell therapy is expected to grow from US$ 75.16 million in 2022 to US$ 139.30 million by 2028. It is estimated to grow at a CAGR of 10.8% from 2022 to 2028.

Use of Induced Pluripotent Stem Cells in Regenerative Medicines Drives South & Central America Stem Cell Therapy Market

Per the Frontiers Media S.A. 2023 report, progress in the field of induced pluripotent stem cells (iPSCs) has opened a new gateway for research in therapeutics. iPSCs are mainly intended for research and clinical studies such as disease modeling, regenerative medicine, and drug discovery/drug cytotoxicity studies. For example, iPSCs can be used to convert differentiated somatic cells to multipotent stem cells to generate different cell types of adult tissues. Thus, iPSCs have shown promising results in regenerative medicine, particularly for replacing diseased or injured cells. iPSCs are widely used to regenerate tissue-specific cells for transplantation in patients for treating injuries and degenerative diseases. Studies such as drug discovery involving screening of small molecules and toxicity testing for safety assessment have been successfully disclosed positive iPSCs-based results. The aforementioned factors are expected to offer lucrative growth opportunities to companies in the South & Central America stem cell therapy market in the coming years.

South & Central America Stem Cell Therapy Overview

The government and healthcare authorities in Brazil are implementing constructive strategies to increase the awareness and exposure of stem cell therapies in the countries. For example, providing international exposure, the authorities are focusing on conducting clinical trials in the country. For instance, according to clinicaltrials.gov, in 2016, around 27 stem cell studies were being conducted in the country, which accounted for an estimated 1.7% of all the stem cell studies across the globe. Also, the country allotted around US$ 5.0 Mn for stem cell research at the starting beginning of the entry in the stem cell domain. Increasing awareness in the country is fueling the growth of innovations and discoveries in the stem cell market. For instance, in 2017, R-Crio, a Brazil-based startup, discovered a way to produce around 7 million stem cells from a single baby tooth. These factors are likely to drive the growth of the Brazil stem cell therapy market during the forecast period.

South & Central America Stem Cell Therapy Revenue and Forecast to 2028 (US$ Million)

South & Central America Stem Cell Therapy Strategic Insights

Strategic insights for the South & Central America Stem Cell Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Stem Cell Therapy Report Scope

South & Central America Stem Cell Therapy Regional Insights

The geographic scope of the South & Central America Stem Cell Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Stem Cell Therapy Segmentation 

The South & Central America stem cell therapy is segmented into type, treatment, application, end user, and country.

Based on type, the South & Central America stem cell therapy is segmented into adult stem cell therapy, embryonic stem cell therapy, induced pluripotent stem cell therapy, and other stem cell therapy. In 2022, the adult stem cell therapy segment registered the largest share in the South & Central America stem cell therapy. The adult stem cell therapy segments is further segmented into hematopoietic stem cell therapy, umbilical cord stem cell therapy, neuronal stem cell therapy, and mesenchymal stem cell.

Based on treatment, the South & Central America stem cell therapy is bifurcated into allogeneic and autologous. In 2022, the allogeneic segment registered a larger share in the South & Central America stem cell therapy.

Based on application, the South & Central America stem cell therapy is segmented into musculoskeletal, dermatology, cardiology, drug discovery & development, and other applications. In 2022, the musculoskeletal segment registered the largest share in the South & Central America stem cell therapy.

Based on end user, the South & Central America stem cell therapy is bifurcated into hospitals & specialty clinics and academic & research institutes. In 2022, the academic & research institutes segment registered a larger share in the South & Central America stem cell therapy.

Based on country, the South & Central America stem cell therapy is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil segment registered the largest share in the South & Central America stem cell therapy.

Lonza Group AG, Pluri Inc, Smith & Nephew Plc, and TiGenix NV (Takeda Pharmaceutical Company Limited) are some of the leading companies operating in the South & Central America stem cell therapy.